Xiao-Dong Yan

Dr. Xiao-Dong Yan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RARui An
Rui An
RYRuihao Yu
Ruihao Yu
XWXinxin Wen
Xinxin Wen
QMQingyang Ma
Qingyang Ma
KMKelei Mao
Kelei Mao
WWWei Wang
Wei Wang
The consensus molecular subtype 4 (CMS4) of colorectal cancer (CRC) represents an aggressive, mesenchymal phenotype associated with the poorest clinical prognosis. Although angiogenesis is fundamental to CRC progression, current anti-VEGF therapies are frequently compromised by primary or acquired resistance, creating an urgent need to identify alternative vascular drivers. NOTCH3 is significantly enriched in CMS4 CRC, yet its direct role in modulating the tumor vasculature remains elusive. Here, integrating multi-center transcriptomic datasets with clinical validation, we identified NOTCH3 as a critical engine of CRC angiogenesis. In Stage IV clinical samples, NOTCH3 expression correlated significantly with microvessel density (MVD). Functionally, overexpression of the NOTCH3 intracellular domain (NICD3) dramatically enhanced endothelial tube formation and migration in vitro, while driving robust tumor vascularization in xenograft models. Through transcriptomic profiling, we identified the secreted factor transforming growth factor-beta-induced protein (TGFBI) as the essential downstream effector. Mechanistically, we demonstrate that NICD3 physically interacts with and upregulates SMAD3, thereby facilitating the direct transcriptional activation of TGFBI. Crucially, to translate these mechanistic insights, we utilized molecular docking and drug screening to identify the flavonoid Hesperidin (HES) as a potent binder of TGFBI. HES treatment effectively abolished NICD3-driven angiogenesis and suppressed tumor progression in vivo. Collectively, our findings characterize a novel NICD3/SMAD3/TGFBI signaling axis as a key vulnerability in CRC and propose HES as a promising precision therapeutic strategy for CRC patients with features of CMS4.

25 July 2025 in Neuroscience
Verified
Journal Article
Open access
KMKelei Mao
Kelei Mao
AGAngyang Guo
Angyang Guo
YLYize Li
Yize Li
WYWendi Yang
Wendi Yang
YXYiduo Xiong
Yiduo Xiong
XYXiao-Dong Yan
Xiao-Dong Yan
Lower-grade glioma (LGG) is a molecularly heterogeneous tumor in which acidic microenvironments and immune interactions critically influence prognosis. Acid-sensing ion channels (ASICs), particularly ASIC1, remain understudied in glioma biology despite their pH-sensing roles. This study investigates ASIC1/ASIC4 in LGG prognosis, immune regulation, and molecular subtyping. Multi-omics analyses integrated TCGA and CGGA datasets (n = 696 LGG) with bioinformatics tools (TIMER, GEPIA, TISIDB). ASIC expression, immune infiltration, and checkpoint molecules were evaluated. Prognostic significance was assessed via Kaplan-Meier, Cox regression, and PrognoScan. Mechanistic links to SOX8 were validated through correlation analyses, functional enrichment, and immunohistochemistry (n = 78 LGG). ASIC1/ASIC4 were upregulated in LGG versus normal tissues and inversely correlated with immune infiltration (B cells, CD8+/CD4+ T cells; P < 0.05). High ASIC1 expression predicted improved survival (HR = 0.38, P = 2.2 × 10-7), independent of age/tumor grade, and showed negative associations with immune checkpoints (PDCD1, CD274; P < 0.01). ASIC1-SOX8 co-expression (Pearson r = 0.73) was enriched in IDH-mutant 1p/19q co-deleted subtypes and grade II tumors. Immunohistochemistry confirmed higher ASIC1/SOX8 protein levels in grade II versus III gliomas (P < 0.05). Functional analyses linked ASIC1 to suppressed inflammatory pathways (IL2-STAT5, complement cascades). The ASIC1-SOX8 axis emerges as a dual prognostic biomarker and molecular subtype regulator in LGG, linking acidic microenvironments to immune evasion and IDH-driven glioma classification. Its clinical relevance in stratifying low-grade, IDH-mutant tumors highlights therapeutic potential for microenvironment-targeted immunotherapy.